Acasti pharma announces interim data meets all primary endpoints for pivotal pk study for gtx-104

Bioavailability of gtx-104 compares favorably with the oral formulation of nimodipine; full pk study expected to report out as planned in h1'22 bioavailability of gtx-104 compares favorably with the oral formulation of nimodipine; full pk study expected to report out as planned in h1'22
ACST Ratings Summary
ACST Quant Ranking